Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATG-F Induction Regimens in Kidney Transplant
NCT02267512Phase 4Completed
- Sponsor
- Astellas Pharma
- Start
- Jul 2012
- Primary completion
- Dec 2015
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of antithymocyte globulin rabbit in kidney transplant rejection (2 arms), sponsored by Astellas Pharma. Primary endpoint: Efficacy failure at 12 months. Started Jul 2012; status: completed.
02
Drugs
antithymocyte globulin rabbit
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT02267512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02267512.